DK2857401T5 - HIDTIL UKENDT ß-LACTAMASEINHIBITOR OG FREMGANGSMÅDE TIL AT FREMSTILLE SAMME - Google Patents

HIDTIL UKENDT ß-LACTAMASEINHIBITOR OG FREMGANGSMÅDE TIL AT FREMSTILLE SAMME Download PDF

Info

Publication number
DK2857401T5
DK2857401T5 DK13796357.5T DK13796357T DK2857401T5 DK 2857401 T5 DK2857401 T5 DK 2857401T5 DK 13796357 T DK13796357 T DK 13796357T DK 2857401 T5 DK2857401 T5 DK 2857401T5
Authority
DK
Denmark
Prior art keywords
procedure
preparing same
lactamase inhibitor
hitherto unknown
hitherto
Prior art date
Application number
DK13796357.5T
Other languages
English (en)
Other versions
DK2857401T3 (da
Inventor
Takao Abe
Takeshi Furuuchi
Yoshiaki Sakamaki
Seiichi Inamura
Akihiro Morinaka
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49673384&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2857401(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Application granted granted Critical
Publication of DK2857401T3 publication Critical patent/DK2857401T3/da
Publication of DK2857401T5 publication Critical patent/DK2857401T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DK13796357.5T 2012-05-30 2013-05-30 HIDTIL UKENDT ß-LACTAMASEINHIBITOR OG FREMGANGSMÅDE TIL AT FREMSTILLE SAMME DK2857401T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012122603 2012-05-30
PCT/JP2013/064971 WO2013180197A1 (ja) 2012-05-30 2013-05-30 新規β－ラクタマーゼ阻害剤とその製造法

Publications (2)

Publication Number Publication Date
DK2857401T3 DK2857401T3 (da) 2019-10-14
DK2857401T5 true DK2857401T5 (da) 2020-01-13

Family

ID=49673384

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13796357.5T DK2857401T5 (da) 2012-05-30 2013-05-30 HIDTIL UKENDT ß-LACTAMASEINHIBITOR OG FREMGANGSMÅDE TIL AT FREMSTILLE SAMME

Country Status (29)

Country Link
US (7) US9181250B2 (da)
EP (1) EP2857401B8 (da)
JP (1) JP6265892B2 (da)
KR (1) KR102108590B1 (da)
CN (3) CN106967066B (da)
AR (2) AR091222A1 (da)
AU (1) AU2013268415B2 (da)
BR (1) BR112014029368B1 (da)
CA (1) CA2874279C (da)
CL (1) CL2014003035A1 (da)
CO (1) CO7151513A2 (da)
DK (1) DK2857401T5 (da)
ES (1) ES2758507T3 (da)
HK (3) HK1206746A1 (da)
HU (1) HUE046893T2 (da)
IL (1) IL235944B (da)
MX (1) MX366948B (da)
MY (1) MY174523A (da)
NZ (1) NZ701959A (da)
PH (1) PH12014502683A1 (da)
PL (1) PL2857401T3 (da)
PT (1) PT2857401T (da)
RU (1) RU2693898C2 (da)
SG (1) SG10201605368UA (da)
SI (1) SI2857401T1 (da)
TW (1) TWI565707B (da)
UA (1) UA117734C2 (da)
WO (1) WO2013180197A1 (da)
ZA (1) ZA201408455B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
CA2868553A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole .beta.-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP2857401B8 (en) 2012-05-30 2019-11-20 Meiji Seika Pharma Co., Ltd. NOVEL ß-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME
KR101946107B1 (ko) * 2012-08-25 2019-02-08 욱크하르트 리미티드 １,６-디아자비시클로〔３,２,１〕옥탄-７-온 유도체 및 세균 감염의 치료에서의 이의 용도
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
CN107501264A (zh) * 2013-09-24 2017-12-22 明治制果药业株式会社 二氮杂二环辛烷衍生物的制备方法
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
KR102487297B1 (ko) 2013-10-08 2023-01-12 메이지 세이카 파루마 가부시키가이샤 디아자비시클로옥탄 유도체의 결정과 그의 제조법
KR102340010B1 (ko) * 2013-10-22 2021-12-16 욱크하르트 리미티드 항균제를 포함하는 제약학적 조성물
BR112016012053A2 (pt) * 2013-11-26 2017-08-08 Wockhardt Ltd Composições antibacterianas
KR20160108409A (ko) * 2014-01-21 2016-09-19 욱크하르트 리미티드 질소 내포 화합물 및 항세균제로서 이들의 용도
NZ728036A (en) * 2014-01-21 2019-12-20 Wockhardt Ltd Pharmaceutical compositions comprising antibacterial agents
IN2014MU01192A (da) 2014-03-29 2015-10-02 Wockhardt Ltd
KR102173632B1 (ko) * 2014-04-18 2020-11-03 욱크하르트 리미티드 항균 물질들을 포함하는 약학 조성물
MX2017006383A (es) 2014-11-17 2017-08-21 Entasis Therapeutics Ltd Terapia de combinacion para el tratamiento de infecciones bacterianas resistentes.
EP3227306B1 (en) * 2014-12-02 2020-07-15 Merck Sharp & Dohme Corp. Process for the preparation of tert-butyl 4-((2s,5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof
TWI691499B (zh) * 2014-12-05 2020-04-21 日商明治製菓藥業股份有限公司 二氮雜雙環辛烷衍生物之結晶及安定的凍結乾燥製劑的製造法
US20180243286A1 (en) * 2015-01-24 2018-08-30 Wockhardt Limited Antibacterial compositions of a beta-lactamase inhibitor with a cephalosporin
WO2016120752A1 (en) * 2015-01-28 2016-08-04 Wockhardt Limited A process for preparation of (2s, 5r)-n-(2-amino ethoxy)-6-(sulfooxy)-7-oxo-1,6- diazabicyclo [3.2.1] octane-2-carboxamide
RU2715058C2 (ru) 2015-03-31 2020-02-25 Мутабилис Гетероциклические соединения и их применение для предупреждения или лечения бактериальных инфекций
WO2017002083A1 (en) * 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
MX2017013792A (es) * 2015-09-16 2018-07-06 Xuanzhu Pharma Co Ltd INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS.
EP3356357A4 (en) 2015-10-02 2019-02-20 LegoChem Biosciences, Inc. COMPOSITIONS AND METHODS OF INHIBITING BETA LACTAMASE
WO2017081615A1 (en) * 2015-11-09 2017-05-18 Wockhardt Limited 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections
WO2017098425A1 (en) * 2015-12-11 2017-06-15 Wockhardt Limited 7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide containing compounds and their use in treating bacterial infections
US10472345B2 (en) 2016-02-04 2019-11-12 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
CN109311881B (zh) 2016-06-03 2021-07-13 齐鲁制药有限公司 新型β-内酰胺酶抑制剂
WO2017216763A1 (en) * 2016-06-17 2017-12-21 Wockhardt Limited N-phenylalkoxy-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide derivatives and their use as antibacterial agents
WO2017216764A1 (en) * 2016-06-17 2017-12-21 Wockhardt Limited N-(alkanoyl)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carbonylhydrazide derivatives and their use as antibacterial agents
CN106397302B (zh) * 2016-07-04 2019-02-26 中国药科大学 一种o-取代羟胺荧光衍生化试剂的制备与纯化方法
KR102537340B1 (ko) 2016-09-16 2023-05-26 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물
EP3515915B1 (en) * 2016-09-19 2021-08-04 Merck Sharp & Dohme Corp. Process for preparing beta-lactamase inhibitor hydroxylurea intermediates
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
KR102611447B1 (ko) 2017-05-08 2023-12-06 엔타시스 테라퓨틱스, 인크. 박테리아 감염을 치료하는 화합물 및 방법
US10085999B1 (en) * 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CN111465604B (zh) * 2017-09-27 2023-05-12 明治制果药业株式会社 二氮杂二环辛烷衍生物的药物形式及其制备方法
CN111447924A (zh) * 2017-09-27 2020-07-24 费多拉制药公司 二氮杂二环辛烷衍生物的药物形式及其制备方法
KR20200091395A (ko) 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법
CN107907604B (zh) * 2017-11-07 2021-01-22 中山奕安泰医药科技有限公司 (2s,5r)-苯氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
CN107941969B (zh) * 2017-11-07 2021-03-02 中山奕安泰医药科技有限公司 (2s,5r)-苯氧胺基哌啶-2-甲酰胺的检测方法
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
CN111417633B (zh) 2017-12-01 2022-05-06 齐鲁制药有限公司 一种β-内酰胺酶抑制剂的晶型及其制备方法
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
CN109970625B (zh) * 2017-12-28 2021-02-26 新发药业有限公司 一种5r-苄氧氨基哌啶-2s-甲酸或其衍生物的制备方法
CN108362789B (zh) * 2018-01-19 2020-09-01 珠海优润医药科技有限公司 一种阿维巴坦钠光学异构体的高效液相色谱检测方法
JP7318950B2 (ja) 2018-05-14 2023-08-01 国立大学法人東海国立大学機構 β－ラクタマーゼ阻害剤
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
WO2020059891A1 (ja) 2018-09-21 2020-03-26 株式会社エーピーアイ コーポレーション アミノ酸誘導体の製造方法
CN111198266A (zh) * 2020-01-09 2020-05-26 深圳市博奥通科生物制品有限公司 舒巴坦快速检测试剂盒
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用１１１１５１５２１３９１９９東京都中央区京橋２丁目３番１３号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (da) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
HUT74682A (en) * 1993-12-29 1997-01-28 Pfizer Diazabicyclic neurokinin antagonists and pharmaceutical compositions containing them
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶，該結晶を含む凍結乾燥製剤，およびその製造方法
ES2183874T3 (es) 1994-05-02 2003-04-01 Shionogi & Co Cristal derivado de pirrolidylthiocarbapenem, preparado liofilizado conteniendo dicho cristal y procedimiento para su produccion.
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
KR100931039B1 (ko) * 2007-10-05 2009-12-10 현대자동차주식회사 가변 밸브 장치
SI2231667T1 (sl) 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta laktamazni inhibitorji
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
US8496548B2 (en) 2010-11-10 2013-07-30 Martin T. Connolly Wide-body arrow having tapered tail
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
EP2657234B1 (en) 2010-12-22 2017-01-11 Meiji Seika Pharma Co., Ltd. Optically-active diazabicyclooctane derivative and method for manufacturing same
EP2678861B1 (en) * 2011-02-22 2018-07-11 Speak With Me, Inc. Hybridized client-server speech recognition
MX361020B (es) 2011-06-17 2018-11-26 Pfizer Anti Infectives Ab Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma.
DE102011111964A1 (de) * 2011-08-31 2013-02-28 Ixetic Bad Homburg Gmbh Verdampfer-Wärmetauscher-Einheit
KR20140068013A (ko) * 2011-08-25 2014-06-05 텔레포나크티에볼라게트 엘엠 에릭슨(피유비엘) 심도맵의 인코딩 및 디코딩
RU2578370C2 (ru) 2011-08-27 2016-03-27 Вокхардт Лимитед Производные 1,6- диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней
RU2570423C2 (ru) * 2011-08-30 2015-12-10 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение при лечении бактериальных инфекций
KR101680933B1 (ko) * 2011-09-13 2016-11-29 욱크하르트 리미티드 질소 함유 화합물 및 이의 용도
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
CA2868553A1 (en) * 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole .beta.-lactamase inhibitors
EP2857401B8 (en) 2012-05-30 2019-11-20 Meiji Seika Pharma Co., Ltd. NOVEL ß-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME
KR101946107B1 (ko) * 2012-08-25 2019-02-08 욱크하르트 리미티드 １,６-디아자비시클로〔３,２,１〕옥탄-７-온 유도체 및 세균 감염의 치료에서의 이의 용도
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
WO2014135931A1 (en) * 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
MX2015011721A (es) * 2013-03-08 2015-12-01 Wockhardt Ltd Proceso para la preparacion de (2s,5r) -7-oxo-6-sulfooxi-2-[((3r)- pirrolidin-3-carbonil) carbonil hidrazino]-1,6-diaza-biciclo[3.2.1 ] octano.
CN107501264A (zh) 2013-09-24 2017-12-22 明治制果药业株式会社 二氮杂二环辛烷衍生物的制备方法
KR102487297B1 (ko) 2013-10-08 2023-01-12 메이지 세이카 파루마 가부시키가이샤 디아자비시클로옥탄 유도체의 결정과 그의 제조법
IN2014MU01192A (da) * 2014-03-29 2015-10-02 Wockhardt Ltd
TWI691499B (zh) 2014-12-05 2020-04-21 日商明治製菓藥業股份有限公司 二氮雜雙環辛烷衍生物之結晶及安定的凍結乾燥製劑的製造法

Also Published As

Publication number Publication date
TW201408668A (zh) 2014-03-01
US9708320B2 (en) 2017-07-18
PH12014502683B1 (en) 2015-01-26
JP6265892B2 (ja) 2018-01-24
ES2758507T3 (es) 2020-05-05
NZ701959A (en) 2016-07-29
HK1222651A1 (zh) 2017-07-07
US11731971B2 (en) 2023-08-22
US10556905B2 (en) 2020-02-11
RU2014153856A (ru) 2016-07-20
CO7151513A2 (es) 2014-12-29
RU2693898C2 (ru) 2019-07-05
SG10201605368UA (en) 2016-08-30
HUE046893T2 (hu) 2020-04-28
RU2019120235A3 (da) 2022-04-01
MY174523A (en) 2020-04-23
PL2857401T3 (pl) 2020-02-28
EP2857401A4 (en) 2015-11-04
US20160024090A1 (en) 2016-01-28
MX2014014653A (es) 2015-02-12
AR124237A2 (es) 2023-03-01
TWI565707B (zh) 2017-01-11
WO2013180197A1 (ja) 2013-12-05
CA2874279A1 (en) 2013-12-05
RU2019120235A (ru) 2019-07-16
SI2857401T1 (sl) 2020-01-31
HK1208862A1 (en) 2016-03-18
CA2874279C (en) 2021-03-16
US20200048253A1 (en) 2020-02-13
CN104334559A (zh) 2015-02-04
AU2013268415A1 (en) 2014-12-04
EP2857401A1 (en) 2015-04-08
BR112014029368A2 (pt) 2017-06-27
US20210371419A1 (en) 2021-12-02
PH12014502683A1 (en) 2015-01-26
MX366948B (es) 2019-07-30
ZA201408455B (en) 2019-09-25
UA117734C2 (uk) 2018-09-25
DK2857401T3 (da) 2019-10-14
JPWO2013180197A1 (ja) 2016-01-21
US11117896B2 (en) 2021-09-14
CN105859609B (zh) 2019-04-09
US20230331724A1 (en) 2023-10-19
IL235944B (en) 2018-01-31
AU2013268415B2 (en) 2017-05-25
CN105859609A (zh) 2016-08-17
EP2857401B8 (en) 2019-11-20
US20150141401A1 (en) 2015-05-21
KR20150015523A (ko) 2015-02-10
US20170233393A1 (en) 2017-08-17
CN106967066B (zh) 2019-07-30
EP2857401B1 (en) 2019-09-18
IL235944A0 (en) 2015-02-01
CN104334559B (zh) 2017-03-22
US9181250B2 (en) 2015-11-10
AR091222A1 (es) 2015-01-21
CL2014003035A1 (es) 2015-01-30
HK1206746A1 (en) 2016-01-15
PT2857401T (pt) 2019-11-19
US10023573B2 (en) 2018-07-17
KR102108590B1 (ko) 2020-05-07
BR112014029368B1 (pt) 2020-10-27
CN106967066A (zh) 2017-07-21
US20180258089A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
DK2857401T5 (da) HIDTIL UKENDT ß-LACTAMASEINHIBITOR OG FREMGANGSMÅDE TIL AT FREMSTILLE SAMME
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2941220T3 (da) Anordning og fremgangsmåde til subgingival måling
DK2854883T3 (da) Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf
DK2970205T3 (da) JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
DK2884999T3 (da) Fremgangsmåde og sammensætninger til cellulær immunterapi
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3355539T3 (da) Fremgangsmåder og indretninger til kanalestimering
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
DK2917763T3 (da) Lidar-målesystem og lidar-målefremgangsmåde
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK2776833T3 (da) Cobinder-understøttet testfremgangsmåde
BR112015007125A2 (pt) aparelho e método
DK2584921T3 (da) Sondeernæringspakninger og fremgangsmåder til anvendelse deraf
DK2908661T3 (da) Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf
DK3930322T3 (da) Fremgangsmåder og anordninger til kodning
DK2898865T3 (da) Pleje-fremgangsmåde og plejerobot, der anvendes ved denne
DK2593797T3 (da) Hidtil ukendte fremgangsmåder til proteinevolution
DK2896694T3 (da) Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3381461T3 (da) Peptider og fremgangsmåder til anvendelse deraf